Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Buprenorphine Maintenance for Opiate Dependence - 6
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000357
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Alternate-Day Buprenorphine Administration. Phase VI - 7
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000225
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Alternate-Day Buprenorphine Administration. Phase IV - 5
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000223
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Alternate-Day Buprenorphine Administration. Phase I - 3
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000221
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Buprenorphine Detoxification - BBDVI - 19
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-08-17
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000237
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Buprenorphine Pharmacology Related to Addiction Treatment - 21
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-08-17
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000239
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Alternate Day Buprenorphine Administration, Phase X - 15
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-08-17
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000233
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Alternate Day Buprenorphine Administration, Phase XII - 17
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-08-17
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000235
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Gradual Vs. Rapid Buprenorphine Detoxification - 2
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000220
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Alternate-Day Buprenorphine Administration. Phase VII - 8
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000226
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.